---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-22-000051"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2022-06-01T23:59:59+00:00"
generated_at: "2026-06-25T05:29:03.074500+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics appoints Ankur Dhingra as CFO with $450k base salary

## Summary
- Ankur Dhingra named CFO effective May 31, 2022, replacing interim CFO Robert W. Duggan (who remains CEO).
- Annual base salary of $450,000; eligible for performance bonus up to 50% of base.
- Granted option to purchase 600,000 shares (10-year term, 4-year graded vesting, strike at grant-date close).
- Dhingra previously CFO at CareDx and held finance roles at Agilent Technologies; also oversees IT and HR.
- No written employment agreement; no family relationships or material transactions disclosed.

## SEC filing metadata
- accession: 0001599298-22-000051
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2022-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/0001599298-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/smmt-20220601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-22-000051
- JSON: https://secwatch.observer/filing/0001599298-22-000051.json
- Plain text: https://secwatch.observer/filing/0001599298-22-000051.txt

## Key facts
- Executive change
  Ankur Dhingra was appointed as Chief Financial Officer at Summit Therapeutics Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective on May 31, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) appointed Ankur Dhingra to serve as Chief Financial Officer and Principal Accounting Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/0001599298-22-000051-index.htm
- Executive change
  Robert W. Duggan changed role as interim principal financial officer at Summit Therapeutics Inc..
  - Role: interim principal financial officer
  source text: Mr. Dhingra will replace Robert W. Duggan, who was acting as the Company’s interim principal financial officer since the departure of Michael Donaldson as Chief Financial Officer on July 2, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000051/0001599298-22-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.